Poster Presentations Highlight Baseline Characteristics from the Phase 3 VANQUISH-2 Trial of Subcutaneous VK2735 and the Impact of VK2735 on Obesity Severity and Cardiometabolic Parameters in the Phase 2 VENTURE
SAN DIEGO, Nov. 3, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine
NEW YORK, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Peptide-based treatments are attracting growing attention from major pharmaceutical companies as researchers push into new ways to treat diabetes, obesity, cancer, metabolic
-- VANQUISH Phase 3 Trials for Subcutaneous VK2735 in Obesity Continue to Advance ---- SUNRISE Phase 3 Trials for Oral VK2735 Initiated ---- Positive Top-Line Results Announced for VK2735 Maintenance Dosing Study; Part
Conference Call Scheduled for Wednesday, October 28, at 4:30 p.m. Eastern Time SAN DIEGO, Oct. 21, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical
SUNRISE -1 and SUNRISE-2 Studies to Evaluate Oral VK2735 in Obese Adults with and without Type 2 Diabetes SAN DIEGO, Oct. 14, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ:VKTX), a clinical-stage
Study to Explore Oral Maintenance Dosing Regimens Following Initial Weight Loss with Subcutaneous VK2735Monthly and Every-Other-Week Subcutaneous Regimens to also be EvaluatedSAN DIEGO, Oct. 6, 2026 /PRNewswire/ --
Gross Proceeds to Viking Approximately $575 MillionSAN DIEGO, Sept. 28, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel
NEW YORK, Sept. 28, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Viking Therapeutics, Inc. (NASDAQ:VKTX) breached their fiduciary
SAN DIEGO, Sept. 24, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today
SAN DIEGO, Sept. 23, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today
DENVER, Sept. 22, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) – The spotlight is heating up across four very different high-catalyst stories: Viking Therapeutics (NASDAQ:VKTX) is pushing its VK2735 obesity program
22% Placebo-Adjusted Weight Loss Reported at Week 33 Following Weekly Dosing of VK2735 at 17.5 mg; No Plateau ObservedResults Demonstrate Viability of Monthly and Every Other Week Dosing Regimens for Maintaining Weight
SAN DIEGO, Sept. 2, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine
